825 results on '"Edwards, Christopher J."'
Search Results
2. Tyrosine kinase 2 inhibitors in autoimmune diseases
3. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
4. Hypotension duration and vasopressor requirements following intrathecal oxytocin for Total hip arthroplasty: Secondary analysis of a randomized controlled trial
5. Comparison of Femoral Nerve Catheter, Adductor Canal Catheter, and Periarticular Liposomal Bupivacaine Infiltration for Postoperative Analgesia After Primary Total Knee Arthroplasty
6. Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)
7. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
8. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
9. Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
10. Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study
11. Casting and Advocacy Model of Training Helpers: Principle-Based Supervision in a Training Clinic to Strengthen Health and Well-Being
12. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
13. Randomized controlled trial of intrathecal oxytocin on speed of recovery after hip arthroplasty
14. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
15. Treating Rheumatoid Arthritis Through the Life Course
16. JAK inhibitors in systemic lupus erythematosus: Translating pathogenesis into therapy.
17. Pain Reduction With Oral Methotrexate in Knee Osteoarthritis: A Randomized, Placebo-Controlled Clinical Trial.
18. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
19. Rheumatoid arthritis in the elderly: Characteristics and treatment considerations
20. Descriptive epidemiology of hip and knee replacement in rheumatoid arthritis: An analysis of UK electronic medical records
21. Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally
22. The RESIST Study: Examining Cognitive Change in Rheumatoid Arthritis Patients with Mild Cognitive Impairment Being Treated with a TNF-Inhibitor Compared to a Conventional Synthetic Disease-Modifying Anti-Rheumatic Drug
23. A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
24. Studies on Values of Digital Health
25. Rheumatoid Arthritis: The Impact of Mental Health on Disease: A Narrative Review
26. The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?
27. Can we wean patients with inflammatory arthritis from biological therapies?
28. Rheumatoid factor testing in Spanish primary care: A population-based cohort study including 4.8 million subjects and almost half a million measurements
29. Differences in management approaches for lupus nephritis within the UK
30. The RESIST Study: Do TNF Inhibitors Protect Against Cognitive Decline in Rheumatoid Arthritis Patients With Mild Cognitive Impairment?
31. Single-Injection Adductor Canal Block With Multiple Adjuvants Provides Equivalent Analgesia When Compared With Continuous Adductor Canal Blockade for Primary Total Knee Arthroplasty: A Double-Blinded, Randomized, Controlled, Equivalency Trial
32. Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?
33. Perineural dexamethasone successfully prolongs adductor canal block when assessed by objective pinprick sensory testing: A prospective, randomized, dose-dependent, placebo-controlled equivalency trial
34. Aging and the use of an in-vehicle intersection crossing assist system: An on-road study
35. Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: An interrupted time-series analysis
36. An Analysis of Real-World Data on the Safety of Etanercept in Older Patients with Rheumatoid Arthritis
37. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
38. Efficacy and Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis: A Post-Hoc Analysis of Randomized Controlled Trials
39. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
40. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
41. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
42. Amongst patients taking biologic therapies for axial spondyloarthritis, which factors are associated with work non-participation?
43. International Survey to Evaluate Current Options for Subcutaneous Injection of Methotrexate (MTX) and a New Button-Free MTX Autoinjector.
44. Evaluation of a Generative Language Model Tool for Writing Examination Questions
45. Reactance Level
46. Coping Style
47. Evaluating residual anti-Xa levels following discontinuation of treatment-dose enoxaparin in patients presenting for elective surgery: a prospective observational trial
48. 180 - Farmacoterapia geriátrica
49. Both rare and common ERAP1 allotypes have distinct functionality defined by polymorphic context and are important in AS association
50. Are there dangers in biologic dose reduction strategies?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.